Legal Issues

Biotech firm in dispute with Canada over genetic test

Published in Cancer Weekly, January 28th, 2003

Myriad Genetics and a Canadian health official are battling over access to a genetic test for inherited forms of breast and ovarian cancer.

Salt Lake-based Myriad Genetics holds both a U.S. and Canadian patent on the use of the BRAC1 and BRAC2 genetic sequence in diagnostic cancer screening tests. Mutations of those genes significantly increase an individual's chance of developing inherited forms of breast or ovarian cancer.

On January 6, 2003, Ontario Health Minister Tony Clement said his government would ignore Myriad's patent and move ahead with blood screening to detect the presence of the mutation.

He said honoring the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-01-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry